Abstract:The quantification of functional C1 inhibitor activity (fC1-INH) is an important tool to diagnose bradykinin-mediated angioedema (AE), whether hereditary or acquired. For that an accurate assay is necessary, therefore we evaluated the analytical performances of a fC1-INH chromogenic assay (Berichrom ® , Siemens) performed utilizing an Optilite turbidimeter (Binding Site). fC1-INH was quantified by means of the chromogenic assay Berichrom ® . Internal quality controls were used to determine the precision of the assay. Stability under various storage and matrix conditions, uncertainty, linearity, interference (of hemolysis, lipemia, and icterus), agreement with the manual Technochrom ® assay, and diagnostic performances were further evaluated on samples from patients and healthy donors. The fC1-INH Berichrom ® assay presented good performances regarding intra- and inter-assay precision (CV: 1.3–4.5 % and 3.0–6.0 %, respectively), expanded uncertainty (5.5 % at normal level and 12.5 % at the clinical threshold) and linearity (rho 2 >0.99: range 7–130 % activity). Addition of interfering substances (hemoglobin <16 g/L, intralipid ® <12 g/L, and bilirubin <1 g/L) did not affect fC1-INH quantification. fC1-INH activity from healthy donors remained stable in citrate whole blood until 4 days at room temperature, and 7 days when plasma was collected. Agreement between the automated Berichrom ® assay and the manual Technochrom ® assay (n=47) was excellent as obtained with both quantitative (Deming regression and Bland–Altman difference plot) and qualitative (Kappa index=1) analyses. Finally, the diagnostic performance of the quantification of fC1-INH for AE evaluated on 81 patients revealed a sensitivity of 100 %, a specificity of 97.2 %, a positive predictive value of 83.3 % and a negative predictive value of 100 %. The automated fC1-INH Berichrom ® assay showed good performance, both at the analytical and diagnostic/clinical levels that allowed its usage in a clinical laboratory for C1-INH-dependent bradykinin-mediated AE research in combination with quantitative C1-INH and C4 determinations.

Establishment and Validation of an Automated System for the Antifactor IIa Assay: A Case Study of Potency Assessment of a Pharmaceutical Gel Formulation

Automated ELISA for potency measurements of therapeutic antibodies and antibody fragments

Enabling accurate measurement of activated factor XI (FXIa) in therapeutic immunoglobulin products

Strategies for Performing Factor Assays in the Presence of Emicizumab or Other Novel/Emerging Hemostatic Agents

Performance Evaluation Of Thrombomodulin, Thrombin-Antithrombin Complex, Plasmin-Alpha 2-Antiplasmin Complex, And T-Pa: Pai-1 Complex

Development of a Rapid Qualitative Screen for Anticoagulant Presence

Clinical Validation of an Automated Fluorogenic Factor XIII Activity Assay Based on Isopeptidase Activity

Development and validation of an in vitro model to study thrombin generation on the surface of catheters in platelet-poor and platelet-rich plasma

The Safety and Efficacy of Novel Agents Targeting Factors XI and XII in Early Phase Human Trials

Comparative field study: impact of laboratory assay variability on the assessment of recombinant factor IX Fc fusion protein (rFIXFc) activity

Automated Processing and Evaluation of Anti-Nuclear Antibody Indirect Immunofluorescence Testing

Large inter-individual variation of the pharmacodynamic effect of anticoagulant drugs on thrombin generation

Quantification of C1 inhibitor activity using a chromogenic automated assay: analytical and clinical performances

Multicenter performance evaluation and reference range determination of a new one-stage factor VIII assay

Activated clotting time in inpatient diagnostic and interventional settings

Global Hemostatic Methods to Tailor Treatment With Bypassing Agents in Hemophilia A With Inhibitors— A Single-Center, Pilot Study

Assay of possible economically motivated additives or native impurities levels in heparin by 1H NMR, SAX-HPLC, and anticoagulation time approaches

Discovery of a new lead molecule to develop a novel class of human factor XIIa inhibitors

Anti-drug Antibody Validation Testing and Reporting Harmonization

[Method comparison between two hemostasis analyzers: STA R Max3 and Cobas t 511]

Direct Determination of Enzymes in Dried Blood Spots by High-Performance Liquid Chromatography – Mass Spectrometry (HPLC-MS) for the Screening of Antithrombotic Agents